A Novel Therapeutic for Parkinson's Disease

Industry:
AI/ML drug discovery for neurology, oncology, genetic diseases

Business Model:
Identify unique product opportunities using AI/ML, perform proof-of-concept (pre)clinical studies, license/ partner with biotech/pharma

Lead Program:
Novel small molecule (SB-0110) for treatment of Parkinson's disease (PD) and levodopa-induced dyskinesia (LID)

Funding To-Date:
$14M in non-dilutive funding from the NIH and The Michael J. Fox Foundation (MJFF)

Development Stage:
IND-enabling studies, starting Phase 1a/b in 2024

Partnering/Funding Opportunity:
Seeking corporate partnering and/or investment funding to complete Ph 1a/b ($12M) or Ph 2 ($30M) clinical studies

Team:
Iman Famili, Ph.D., CEO
Aarash Bordbar, Ph.D., CTO
Tanya Simuni, M.D., CMO
Hiroko Masamune, Ph.D., CDO

Scientific Advisory Board:
World-class KOLs in PD and drug dev:
Kalpana Merchant, Ph.D.
David Weiner, M.D.
Tanya Simuni, M.D.

Contact Information:
Iman Famili, CEO
ifamili@sinopiabio.com

www.sinopiabio.com
Located at JLABS San Diego

Sinopia Biosciences is leveraging an AI/machine learning platform to identify first-in-class therapeutics in neurology, oncology, and genetic diseases. Sinopia is studying diseases and compounds at an unprecedented biomolecular level, enabled by advances in data-driven technologies and data analytics using Sinopia's LEADS™ (LEarn And DiScover) drug discovery platform. LEADS™ has successfully identified two therapeutic opportunities, including a novel therapy for Parkinson's disease and levodopa-induced dyskinesia (PD/LID).

The Challenge:
PD is the fastest growing neurological disorder worldwide (7M patients globally). Levodopa (L-DOPA) is the first and still the best treatment for PD, however long-term use of L-DOPA results in dyskinesia and motor fluctuations in virtually all patients. **Dyskinesia and motor fluctuations are the largest unmet needs in PD outside of a cure**.

Replacing the Standard of Care in Parkinson's Disease: Sinopia's therapeutic candidate offers a number of key advantages

- **First-in-class** small molecule (targeting PKA-RII) with a **dual effect** to address both the symptoms of Parkinson's disease (PD) and levodopa-induced dyskinesia (LID), with potential for **cognitive benefits**.
- **Large and consistent pre-clinical efficacy** in highly translatable primate and rodent models of PD motor symptoms, in both acute and chronic treatments.
- **Strong patent position** (issued patents and composition of matter filings by Sinopia), with additional filings for **other CNS indications**.

Strong anti-LID effect in primates. SB-0107, Sinopia's parent compound; SB-0110, Sinopia's clinical candidate; Amantadine, the only approved LID drug that has significant side effects.



- **Favorable safety profile** demonstrated in multi-year clinical trials under chronic usage with elderly patients.
- High value opportunity with projected **peak annual US sales of $1.2B**.

Capital Efficient Discovery Platform with Multiple Product Opportunities:



High Value Investment Opportunity:
Sinopia is seeking corporate partnering and/or Series A financing to complete a Phase 1a/b ($12M) or Phase 2 ($30M) clinical trial, **augmented with $5.3M funding from NIH/MJFF** (committed in 2021).